Alpine Woods Capital Investors’s Haemonetics HAE Stock Holding History

Alpine Woods Capital Investors’s Portfolio HAE Stock Details HAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-22,490	Closed	-$1.5M	–	224
2021 Q2	$1.5M	Buy	22,490 +97	+0.4%	+$6.86K	0.16%	132
2021 Q1	$2.49M	Buy	22,393 +11	+0%	+$1.36K	0.28%	114
2020 Q4	$2.66M	Buy	22,382 +5,038	+29%	+$542K	0.32%	101
2020 Q3	$1.51M	Buy	+17,344	New	+$1.52M	0.23%	123
2019 Q3	–	Sell	-2,277	Closed	-$274K	–	269
2019 Q2	$274K	Sell	2,277 -3,011	-57%	-$296K	0.06%	238
2019 Q1	$463K	Buy	5,288 +22	+0.4%	+$2K	0.1%	183
2018 Q4	$527K	Sell	5,266 -354	-6%	-$37.2K	0.13%	164
2018 Q3	$644K	Buy	5,620 +100	+2%	+$10.4K	0.13%	132
2018 Q2	$495K	Buy	5,520 +2,300	+71%	+$194K	0.11%	151
2018 Q1	$236K	Buy	+3,220	New	+$221K	0.01%	367

Other funds holding HAE

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

LCP

LGT Capital Partners Pfaeffikon, Switzerland $1.88B AUM 20.37% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Alpine Woods Capital Investors's HAE Position: Q3 2021 in Review

Alpine Woods Capital Investors sold out of Haemonetics (HAE) in Q3 2021, closing a stake of 22,490 shares — an estimated $1.5M sold.

Alpine Woods Capital Investors first reported a position in HAE in Q1 2018 and held it in 10 quarters. The position peaked at $2.66M in Q4 2020. 245 funds tracked by Wall St. Rank hold HAE as of Q3 2021.

Alpine Woods Capital Investors reported no remaining Haemonetics position as of Q3 2021 after selling out during the quarter.
Alpine Woods Capital Investors sold 22,490 Haemonetics shares in Q3 2021, an estimated $1.5M.
Alpine Woods Capital Investors first reported a position in Haemonetics in Q1 2018 and held it in 10 quarters.
Alpine Woods Capital Investors's Haemonetics position peaked at $2.66M in Q4 2020.
245 funds tracked by Wall St. Rank held Haemonetics as of Q3 2021.

Based on Alpine Woods Capital Investors's 13F filing for Q3 2021, filed 12 Nov 2021.